DV
Dividend Vision

XDNA — Kelly CRISPR & Gene Editing Technology ETF

Kelly CRISPR & Gene Editing Technology ETF (XDNA)

XDNA carries a 0.78% expense ratio. Total return is 237.4% over the past 4.6 years, 164.6 points ahead of SPY at 72.8%. Its deepest 1-year drawdown was 8.3%.

The Kelly CRISPR & Gene Editing Technology ETF is an equity ETF that does not currently distribute income to shareholders. With an expense ratio of 0.78% and assets under management of approximately $2.6 million, this fund appeals primarily to growth-oriented investors seeking exposure to companies in the gene editing and CRISPR technology sectors rather than those prioritizing current income.

XDNA key facts

Issuer
Kelly ETFs
Asset type
ETF
Asset class
Equity
Expense ratio
0.78%
Trailing yield
0.13%
Last close
$7.50
AUM
$2,584,623
Average volume
5044.0
Ex-dividend date
12/08/2023
Payment date
12/12/2023